Bioanalytical Sciences, ImmunoGen Inc., 830 Winter St., Waltham, MA 02451 United States.
Antibody Engineering, ImmunoGen Inc., 830 Winter St., Waltham, MA 02451 United States.
J Pharm Biomed Anal. 2019 Sep 10;174:500-508. doi: 10.1016/j.jpba.2019.06.021. Epub 2019 Jun 18.
Host cell proteins (HCPs) are process-related impurities derived from the host organism such as Chinese hamster ovary (CHO) cells used for the production of therapeutic mAbs in biopharmaceuticals and potentially pose a risk to patient safety and product efficacy. A number of HCPs have been reported as exceptionally difficult to remove and persist across downstream purification operations into final drug product because they exhibit association with mAbs. Therefore, understanding of HCP impurities and the mAb itself will provide insights into the rational design of efficient downstream process. The aim of this work is to understand mAb interaction with HCPs and identify co-purified HCP subpopulations using two different approaches: (1) Incubation of purified mAb with harvest cell culture fluid (HCCF) from mock-transfected CHO cells (null HCCF) or (2) Immobilization of mAb onto chromatography media followed by incubation with null HCCF. CHO HCP ELISA was used to semi-quantitatively measure the levels of total HCPs. Orthogonal techniques including 2-DE and LC-MS/MS were applied to detect variations in CHO HCP profiles and species. The HCP contents in protein A product pools were significantly higher compared to that in control sample without mAb spiked in and variable HCP levels shown in three different protein A product pools. The majority of HCPs identified by LC-MS/MS in the three protein A product pool showed overlap with the HCP identified in eluate pools from the column immobilized with three different mAbs. The interacting HCPs associated with mAbs were largely involved in catalytic activity. Both approaches demonstrated mAbs bind a common set of HCPs as well as HCPs unique to the mAb.
宿主细胞蛋白(HCPs)是在生物制药中用于生产治疗性单抗的宿主生物体(如中国仓鼠卵巢(CHO)细胞)产生的与工艺相关的杂质,可能对患者安全和产品疗效构成风险。已经报道了许多 HCPs 非常难以去除,并在下游纯化操作中一直存在于最终药物产品中,因为它们与单抗结合。因此,对 HCP 杂质和单抗本身的了解将为高效下游工艺的合理设计提供深入的见解。这项工作的目的是了解单抗与 HCPs 的相互作用,并使用两种不同的方法鉴定共纯化的 HCP 亚群:(1)用模拟转染 CHO 细胞的收获细胞培养液(无 mAb 的 HCCF)孵育纯化的单抗;或(2)将 mAb 固定在色谱介质上,然后用无 mAb 的 HCCF 孵育。CHO HCP ELISA 用于半定量测量总 HCPs 的水平。应用正交技术,包括 2-DE 和 LC-MS/MS,来检测 CHO HCP 图谱和物种的变化。与未添加 mAb 的对照样品相比,蛋白 A 产物池中的 HCP 含量明显更高,并且在三个不同的蛋白 A 产物池中显示出可变的 HCP 水平。通过 LC-MS/MS 在三个蛋白 A 产物池中鉴定的 HCP 与在三种不同单抗固定柱的洗脱液池中鉴定的 HCP 大部分重叠。与单抗相互作用的 HCPs 主要涉及催化活性。这两种方法都证明了单抗与一组共同的 HCPs 以及单抗特有的 HCPs 结合。